74 related articles for article (PubMed ID: 1519927)
1. [Pharmacokinetics and toxicological study on the intraperitoneal administration of cisplatin and etoposide in gynecological malignancies].
Fujimoto R; Yanagawa Y; Yamada T; Ueki K; Takahara T; Kumagai K; Okamura S; Ueki M; Sugimoto O
Gan To Kagaku Ryoho; 1992 Sep; 19(11):1843-9. PubMed ID: 1519927
[TBL] [Abstract][Full Text] [Related]
2. Phase I/pharmacokinetic study of intraperitoneal cisplatin and etoposide.
Zimm S; Cleary SM; Lucas WE; Weiss RJ; Markman M; Andrews PA; Schiefer MA; Kim S; Horton C; Howell SB
Cancer Res; 1987 Mar; 47(6):1712-6. PubMed ID: 3815369
[TBL] [Abstract][Full Text] [Related]
3. Phase I pharmacokinetic study of intraperitoneal etoposide.
O'Dwyer PJ; LaCreta FP; Daugherty JP; Hogan M; Rosenblum NG; O'Dwyer JL; Comis RL
Cancer Res; 1991 Apr; 51(8):2041-6. PubMed ID: 2009523
[TBL] [Abstract][Full Text] [Related]
4. [Significance and effects of intraperitoneal cisplatin administration for ovarian cancer].
Shimizu A; Ookubo K; Hasegawa J; Endoh T; Fujiwara O; Yoda A; Okuyama D; Narabayashi A; Kimura T; Takahashi J; Notake Y
Gan To Kagaku Ryoho; 1999 Oct; 26(12):1801-5. PubMed ID: 10560398
[TBL] [Abstract][Full Text] [Related]
5. [Chemotherapy in malignant gynecologic tumors using intraperitoneal catheter with a subcutaneous reservoir].
Shimizu A; Kimura T; Funatsu M; Hada Y; Araki H; Notake Y
Gan To Kagaku Ryoho; 1991 Aug; 18(11):1795-9. PubMed ID: 1877820
[TBL] [Abstract][Full Text] [Related]
6. [Correlations between clinical pharmacodynamics and pharmacokinetics of cisplatin and etoposide].
Desoize B; Maréchal F; Cattan A
Ann Biol Clin (Paris); 1993; 51(2):125-8. PubMed ID: 8214810
[TBL] [Abstract][Full Text] [Related]
7. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
Malmström H; Rasmussen S; Simonsen E
Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
[TBL] [Abstract][Full Text] [Related]
8. Intraperitoneal administration of cisplatin and etoposide during surgery for patients with gastric cancer.
Tsujitani S; Watanabe A; Abe Y; Maehara Y; Sugimachi K; Kaibara N
Anticancer Res; 1993; 13(6B):2497-9. PubMed ID: 8135489
[TBL] [Abstract][Full Text] [Related]
9. [The value of a Tenckhoff catheter in ovarian cancer].
Kato N; Arakawa A; Yasui Y; Suzumori K; Suzumori K; Yagami Y
Gan To Kagaku Ryoho; 1991 May; 18(6):1025-30. PubMed ID: 2029187
[TBL] [Abstract][Full Text] [Related]
10. [Intraperitoneal chemotherapy of CDDP and etoposide in patients with advanced ovarian cancer].
Hirashima Y; Shimura T; Tanaka Y; Demukai H; Kubota T; Kobayashi T; Suzuki A
Gan To Kagaku Ryoho; 1993 Aug; 20(10):1321-6. PubMed ID: 8346930
[TBL] [Abstract][Full Text] [Related]
11. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
Miller AA; Rosner GL; Ratain MJ; Hollis DR; Green MR; Schilsky RL
Clin Cancer Res; 1997 May; 3(5):719-25. PubMed ID: 9815741
[TBL] [Abstract][Full Text] [Related]
12. [Intraperitoneal (i.p.) chemotherapy in the management of ovarian cancer--pharmacokinetics and methods of sequential i.p. chemotherapy].
Noda T; Adachi S; Yamamoto T; Hirooka C; Kiyozuka Y; Adachi S; Oku M; Ichijo M
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1561-8. PubMed ID: 2389949
[TBL] [Abstract][Full Text] [Related]
13. Pharmacologic study of etoposide and cisplatin by the intraperitoneal route.
O'Dwyer PJ; LaCreta F; Hogan M; Rosenblum N; O'Dwyer JL; Comis RL
J Clin Pharmacol; 1991 Mar; 31(3):253-8. PubMed ID: 2019667
[TBL] [Abstract][Full Text] [Related]
14. [Analysis of side effects of a combination chemotherapy of cisplatin and adriamycin in gynecological malignancies: comparison between intravenous and intraarterial administration].
Kawagoe K; Tsunoda H; Iijima S; Yokota H; Shigemitsu S
Gan To Kagaku Ryoho; 1984 Mar; 11(3):452-7. PubMed ID: 6538404
[TBL] [Abstract][Full Text] [Related]
15. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.
Muggia FM; Groshen S; Russell C; Jeffers S; Chen SC; Schlaerth J; Curtin J; Morrow CP
Gynecol Oncol; 1993 Aug; 50(2):232-8. PubMed ID: 8375739
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
Minami H; Horio Y; Sakai S; Saka H; Shimokata K
Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
[TBL] [Abstract][Full Text] [Related]
18. Clinical and pharmacokinetic study of intraperitoneal cisplatin at two dose levels: 100 mg/m2 alone or 200 mg/m2 with i.v. sodium thiosulfate.
Canal P; de Forni M; Chatelut E; Chevreau C; Johnson NP; Houin G; Bugat R
Acta Med Austriaca; 1989; 16(3-4):84-6. PubMed ID: 2609919
[TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetics study of intraperitoneal cisplatin in ovarian carcinoma].
Han GR; Cai GF
Zhonghua Fu Chan Ke Za Zhi; 1993 Apr; 28(4):224-6, 254. PubMed ID: 8404307
[TBL] [Abstract][Full Text] [Related]
20. [Clinical evaluation of granisetron hydrochloride against nausea and vomiting induced by anticancer drugs for gynecological malignant tumors].
Kitada M; Sawaragi I
Gan To Kagaku Ryoho; 1996 Jan; 23(1):87-91. PubMed ID: 8546476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
